Microglial inflammasome activation drives developmental white matter injury

Abstract Injury to the developing brain during the perinatal period often causes hypomyelination, leading to clinical deficits for which there is an unmet therapeutic need. Dysregulation of inflammation and microglia have been implicated, yet the molecular mechanisms linking these to hypomyelination are unclear. Using human infant cerebrospinal fluid (CSF) and postmortem tissue, we found that microglial activation of the pro‐inflammatory molecular complex the NLRP3 inflammasome is associated with pathology. By developing a novel mouse brain explant model of microglial inflammasome activation, we demonstrate that blocking the inflammasome rescues myelination. In human and mouse, we discovered a link between the inflammasome product IL1β and increased levels of follistatin, an endogenous inhibitor of activin‐A. Follistatin treatment was sufficient to reduce myelination, whereas myelination was rescued in injured explants upon follistatin neutralization or supplementation with exogenous activin‐A. Our data reveal that inflammasome activation in microglia drives hypomyelination and identifies novel therapeutic strategies to reinstate myelination following developmental injury.

Here, we asked whether microglia cause hypomyelination in developing brain via activation of the pro-inflammatory molecular complex the NLRP3 inflammasome, which has been previously linked to both dysregulated microglia activation and white matter injury in the adult CNS (Barclay & Shinohara, 2017;Denker et al., 2007;Inoue, Williams, Gunn, & Shinohara, 2012). We demonstrate microglial activation of the NLRP3 inflammasome to be a key pathological driver of developmental hypomyelination. We also reveal a hitherto unrecognized link between microglial inflammasome activation and regulation of activin-A signaling, which limits developmental myelination after injury. Together, our findings identify novel therapeutic strategies to restore myelination following perinatal brain injury.

| Animal husbandry
All experiments were performed under V.E.M.'s United Kingdom Home Office project license issued under the "Animals (scientific procedures) Act 1986" and with approval of the Animal Welfare and Ethics Review Body. Animals were housed in a 12 hr light/dark cycle with unrestricted access to food and water. ARRIVE guidelines have been followed for this study. Cultures were maintained at 37 C and 5% CO 2 and media was changed every 2-3 days. At 7 days in vitro (DIV), inflammasome activation was induced in explants first by exposure to 100 ng/ml lipopolysaccharide from Escherichia coli (LPS; 0127:B8; Sigma) for 2 hr, then following washes with media, explants were cultured in fresh media in hypoxic conditions (3% O 2 ) for 3 days until 10 DIV. In a subset of experiments, explants were treated with GdCl 3 (270 μM, Sigma), MCC950 (10 μM, Selleck Chemicals), Ac-YVAD (100 μM, Cambridge Bioscience), activin-A (10 ng/ml, R&D systems) or vehicle controls during LPS and hypoxia exposure from 7 to 10 DIV. In a subset of experiments, a follistatin neutralizing antibody (10 μg/ml; R&D Systems) or goat IgG isotype control (10 μg/ml; R&D Systems) was applied during LPS and hypoxia exposure from 7 to 10 DIV, or recombinant follistatin (10 ng/ml; R&D Systems) or vehicle control was applied to uninjured explants from 7 to 10 DIV. Explants were fixed with 4% paraformaldehyde (PFA; Sigma) for 10 min.

| Immunofluorescent staining of explants
Fixed explants were blocked in 5% normal horse serum (GIBCO) and 0.3% Triton-X-100 (Fisher Scientific) for 1 hr. Primary antibodies diluted in block were applied in a humid chamber at 4 C for 48 hr.
Death was further assessed in explants by live incorporation of a marker of compromised membrane integrity, propidium iodide (PI, 25 μg/ml; Sigma-Aldrich), for 1 hr prior to fixation in the dark.
Explants were counterstained with Hoechst and mounted onto glass slides using Fluoromount-G (Southern Biotech). Images were captured as Z-stacks using an Olympus 3i Spinning Disk microscope and presented as maximum projections using SlideBook 6 software.

| Enzyme-linked immunoabsorbant assay
Levels of TNF-α or follistatin in conditioned media collected from explants were measured by ELISA according to the manufacturer's instructions (R&D Systems; RayBiotech). Absorbance was read at 450 nm on a spectrophotometer and sample concentrations calculated using the equation generated from the standard curve.

| Western blotting
Explants were washed in ice-cold PBS, scraped off the mesh into RIPA buffer (Sigma-Aldrich) supplemented with Thermo Scientific Halt protease and phosphatase inhibitor cocktail, and homogenized with a 23-gauge needle. Samples were shaken at 4 C for 30 min, then centrifuged at 13,000 rpm for 10 min at 4 C. Samples were stored at −80 C until use. Protein concentrations were determined using the BCA Protein Assay Kit (Pierce) according to the manufacturer's instructions. Samples were diluted in Laemmli buffer (Bio-Rad), supplemented with 5% mercapto-ethanol, and heated at 95 C for 2 minutes. Five microgram of protein per sample was loaded onto 4-15% pre-cast polyacrylamide gels (Bio-Rad). Gel electrophoresis was performed in Tris-hydroxyethyl piperazineethanesulfonic acid (HEPES)-sodium dodecyl sulfate (SDS) running buffer (Thermo Scientific) at 100 V for 45 min. Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore) for 2 hr at 10 V in 10% Pierce transfer buffer (Thermo Scientific) and 20% methanol diluted in water. Membranes were blocked with 4% bovine serum albumin (BSA) in Tris-buffered saline with 0.1% Tween-20 (vol/vol) (TBST) for 1 hr at room temperature on an orbital shaker. Rabbit anti-IL1β (1:1000, Abcam) was applied overnight at 4 C, washed thrice in TBST for 10 min and incubated with horseradish peroxidaseconjugated secondary antibody (1:2000; Cell Signalling Technology) for 1 hr at room temperature. Chemiluminescent substrate detection reagent ECL SuperSignal (Thermo Scientific) was applied and digital imaging was performed using the LI-COR Odyssey Fc system. For loading control, membranes were re-blotted with mouse anti-β-actin antibody (1:2000, Cell Signalling Technology) then secondary antibody, and imaged as above.
2.6 | Data mining of in vivo mouse model of perinatal brain injury A microarray gene expression dataset of microglia isolated from a perinatal brain injury model was mined for expression of follistatin F I G U R E 1 Microglial inflammasome activation in human perinatal brain injury. (a) Normalized values for IL1β protein levels in CSF of term and preterm infants. Two-tailed Student's t test, p = .0468. n = 11 preterm, 15 term cases. (b) Non-injured and injured regions of human infant brain stained for MBP (purple) and counterstained with Hoechst (blue). Scale bars, 100 μm. (c) Injured and noninjured regions of human infant brain demonstrating NLRP3 (blue) and CD68 (red) double positive cells (arrows), counterstained with Hoechst (turquoise). Scale bar, 20 μm. (d) Densities of NLRP3+ CD68+ cells/mm 2 in human developing white matter. Paired t-test, p = .0148, n = 5 cases. (e) Densities of iNOS+CD68+ cells/mm 2 in healthy control versus injured human infant brain. Mann-Whitney test, p = .0451. n = 5 control cases and 8 injured cases. (f) iNOS+ (blue) CD68+ (red) double positive microglia (arrows) in noninjured controls and injured case tissue. Scale bar, 20 μm. (i) NLRP3+CD68+ cells/ mm 2 versus ENPP6+ cells/mm 2 in injured and non-injured regions. n = 5 cases. (j) Representative images of ENPP6+ cells in injured and noninjured regions of infant brain. Scale bar, 20 μm. (k) Mean gene expression of CASP1, MAG and MOG in human fetal brain at 12 gestational weeks (gw), fold over levels at 9 gestational weeks (Fst) (Krishnan et al., 2017). This data was generated following intraperitoneal injections of recombinant mouse interleukin-1β (10 μg/kg) or PBS vehicle control into male Swiss mice (OF1) twice a day from P1-4 and once at P5. Four hours postinjection, mice were sacrificed by perfusion with 0.9% sodium chloride. Mice were randomly allocated to treatment groups by alternating allocation. Brains were F I G U R E 2 Brain explant model of microglia inflammasome activation. (a) Diagram of mouse forebrain explant model. Explants are isolated from postnatal day 0 pups. At 7 days in vitro (DIV) when oligodendrocyte precursors are abundant, explants are exposed to lipopolysaccharide (LPS) for 2 hr followed by hypoxia (3% O 2 ) for 3 days until 10 DIV. Untreated explants (Unt) mirror in vivo oligodendrocyte maturation, at 7 DIV showing abundance of oligodendrocyte precursors (O4+; magenta) and paucity of myelin (MBP+; magenta) on axons (NF+; green), and myelination then being robust by 21 DIV. Scale bar, 25 μm. (b) Control and LPS/Hypoxia exposed explants at 10 DIV immunostained for cleaved caspase-1 (p20; green) and CD68 (purple), counterstained with Hoechst (blue). Examples of double positive cells are indicated by arrows. Scale bar, 25 μm. (c) Average cleaved caspase-1 (p20)+CD68+ cells/ field in control and LPS/Hypoxia exposed explants at 10 DIV. Two-tailed Student's t test, p = .0018, n = 3-4 mice/group. (d) Western blot of control (Ctrl) or LPS/Hypoxia (L/H)-exposed explants demonstrating pro-IL1β (30 kDa) and mature IL1β (17 kDa), against loading control Actin. (e) Quantification of intensity of mature IL1β signal in western blots normalized to actin signal, represented as relative units. Two-tailed Student's t test, p = .0340, n = 3 mice/group. (f) Control or LPS/Hypoxia-treated explants at 10 DIV stained for iNOS (green) and CD68 (purple). Examples of double positive cells are indicated by arrows. Scale bar, 25 μm. (g) Mean number of iNOS+ CD68+ cells per field in control and LPS/Hypoxia-exposed explants. Two-tailed Student's t test, p = .0007, n = 7 mice/group. ND = not detected. (h) Concentration of TNF-α (pg/ml) secreted from control and LPS/Hypoxia-exposed explants from 7 to 10 DIV. Two-tailed Student's t test, p = 0.0049, n = 3 mice/group. ND = not detected dissociated using the Neural Tissue Dissociation Kit containing papain and the gentle MACS Octo Dissociator with Heaters (Miltenyi).
Microglia were isolated by magnetic bead associated cell sorting using the CD11B antibody (1:10; Miltenyi) according to the manufacturer's instructions. RNA was extracted and hybridized to Agilent Whole Genome Oligo Microarray (8x60K). Background corrected Log 2 F I G U R E 3 White matter pathology in inflammasome-activated brain explants. (a) Oligodendrocyte lineage cell (Olig2+; green) proliferation (Ki67+; red) in control and LPS/Hypoxia-exposed explants at 8 DIV. Examples of double positive cells are indicated by arrows. Scale bar, 25 μm. (b) Mean number of Ki67+ Olig2+ cells per field at 8 DIV in control and LPS/Hypoxia exposed explants. Two-tailed Student's t test, p = .0018. n = 5 mice/group. (c) Oligodendrocyte lineage cell (Olig2+; red) apoptosis (TUNEL+; green) in control and LPS/Hypoxia-exposed explants at 8 DIV. Double positive cells indicated by arrows. Scale bars, 10 μm. (d) Mean number of TUNEL+ Olig2+ cells per field at 8 DIV in control and LPS/Hypoxia exposed explants. Two-tailed Student's t test, p = .0021. n = 5 mice/group. (e) Mean number of NG2+ or cytoplasmic Olig1 + Olig2 + cells per field at 10 DIV in LPS/Hypoxia-exposed explants normalized to untreated control (dotted line). One sample t test, p = .0359 (NG2+) and 0.0144 (Olig1 + Olig2+). n = 10 and 3 mice/group, respectively. (f) OPCs (NG2+; green) in control and LPS/Hypoxia-exposed explants at 10 DIV. Scale bar, 25 μm. (g) Differentiating oligodendrocytes identified by cytoplasmic Olig1 (green) and nuclear Olig2 expression (purple) in control and LPS/Hypoxia-exposed explants at 10 DIV. Scale bar, 25 μm. (h) Myelination index at 10 and 21 DIV in untreated control and LPS/Hypoxia-exposed explants. Two-tailed Student's t test, p = .0076 and 0.0192, respectively, n = 3-5 mice/group. (i) Myelination at 21 DIV in explants that were untreated (control) or exposed to LPS/Hypoxia, indicated by MBP (magenta) and NF (green). Scale bar, 20 μm intensity data were quantile-normalized and assigned p values based on intensity levels and proximity to baseline, with p < .05 taken to be statistically significant. Mean expression values from PBS controls were subtracted from the IL-1β value at the respective time point. In the published study, the authors confirmed that the cells isolated for gene expression were microglia by flow cytometry (CD11b + CD45 lo F480 hi Ly6G − ) and were not neutrophils (Ly6G + ) or monocytes (CD45 hi ). Furthermore, qPCR analysis of isolated cells found no expression of genes associated with oligodendrocytes, astrocytes, or neurons (Krishnan et al., 2017). Regions of interest were defined for analysis using Zeiss Zen2 software and representative fields of 360 μm × 360 μm were counted, and counts were multiplied to determine density of immunopositive cells per mm 2 .

| Human infant cerebrospinal fluid analysis
The neonatal cohort used in this study has been previously described (Boardman et al., 2018). Sampling was carried out in accordance with the recommendations of UK National Research Ethics Service and South East Scotland Research Ethics Committee (14/SS/044) with written consent from parents of all subjects. We selected 11 preterm infants and 15 term neonates with a C-Reactive Protein level of >1 mg/L, previously used as a proxy for subclinical inflammation (Fond, Lancon, Auquier, & Boyer, 2018). Infants with CRP >1 mg/L had reduced levels of proteins associated with healthy myelination (IGF1: 0.79 fold; SPP1: 0.64 fold; GAL3: 0.17 fold) suggestive of white matter pathology. For preterm versus term infants, the mean birthweights were 1,026 and 3,473 g, the percentage of males in each cohort was 72 and 80%, and the mean age at birth was 27.24 and 39.96 gestational weeks, respectively. No infants in either group had meningitis. We analyzed data previously generated from a custom antibody array (Tebu-Bio/Ray Biotech) as described previously (Boardman et al., 2018) and used data post-background normalization.

| Statistics
Volocity 6.3 software (Perkin Elmer) was used to calculate area of colocalization between MBP and neurofilament; these values were normalized to total area of neurofilament to account for variation in axonal densities ("myelination index"). Western blots were quantified using Image Studio Lite v5.2 software. All manual counts were carried out in a blinded manner. Mean ± SEM are shown in graphs. Data handling and statistical processing performed using Microsoft Excel and GraphPad Prism 8 software.
F I G U R E 5 Legend on next page.
We then asked whether this microglial inflammasome activation in the explant model was associated with white matter pathology. We found that compared to control, LPS and hypoxia treatment significantly increased oligodendrocyte lineage cell (Olig2+) proliferation (c) Diagram of in vivo model of perinatal brain injury induced by intraperitoneal injections of IL1β from postnatal day (P) 1 through 5, with hypomyelination observed by P10. (d) Fold change in expression of the follistatin gene (Fst) in microglia following IL1β treatment in vivo compared to PBS-injected control, at P1, P5, and P10. (e) Mean follistatin levels (pg/ml) in conditioned media of 10 DIV explants which were untreated or exposed to LPS/Hypoxia. Student's t test, p = .0255, n = 3 mice per condition. (f) Diagram of treatment of healthy explants or LPS/Hypoxia-exposed explants with recombinant follistatin or vehicle from 7 to 10 DIV. (g) MBP (purple) and NF (green) in explants with no injury at 10 DIV following treatment with Vehicle or Follistatin. Scale bar, 20 μm. (h) Myelination index at 10 DIV for explants without injury or those exposed to LPS/Hypoxia and treated with Follistatin, normalized to values from vehicle control in each respective condition (dotted line). One sample t-test against value of 1, No injury p = .0188, LPS/Hypoxia p = .0030. n = 3 mice/group. (i) Diagram of treatment of explants with anti-follistatin IgG or isotype IgG during LPS/Hypoxia exposure from 7 to 10 DIV. (j) MBP (purple) and NF (green) in LPS/Hypoxia-exposed explants at 10 DIV following treatment with Anti-Follistatin IgG or control Isotype IgG. Scale bar, 20 μm. (k) Myelination index at 10 and 21 DIV in LPS/Hypoxia-exposed explants treated with anti-Follistatin IgG, normalized to values from isotype IgG control at each time point (dotted line). One sample t-test against value of 1, p = .0276. n = 3 mice/group. (l) Diagram of treatment of explants with recombinant activin-A or vehicle control during LPS/Hypoxia exposure from 7 to 10 DIV. (m) Myelination index at 21 DIV of untreated explants or those exposed to LPS/Hypoxia and treated with either vehicle or activin-A from 7 to 10 DIV. Two-tailed Student's t test, Untreated versus Vehicle p = .0014, Vehicle versus Activin-A p = .0063. n = 5-10 mice/group. (n) LPS/Hypoxia-treated explants treated with vehicle control or activin-A and stained for MBP (purple) and neurofilament (green) at 21 DIV. Scale bar, 75 μm (cytoplasmic Olig1+ Olig2+) relative to control (Figure 3e-g); all NG2+ cells in the explant corpus callosum were positive for the oligodendrocyte lineage marker Olig2 ( Figure S2e). In contrast, treatment with LPS or hypoxia alone had no impact on oligodendrocyte lineage cell number, proliferation, or differentiation ( Figure S2f-h), consistent with previous findings (van Tilborg, Achterberg, et al., 2018). The combination of LPS and hypoxia treatment caused hypomyelination by 10 and 21 DIV, as quantified by area of co-localization between myelin protein (MBP) and the axonal marker neurofilament (NF), normalized to total NF area ("myelination index"; Figure 3h- Having developed a model showing microglial inflammasome activation and hypomyelination, we then tested whether there was a causal relationship between the two findings. We applied gadolinium chloride (GdCl 3 ) which inhibits the inflammasome and reduces proinflammatory microglia activation following white matter damage (Kim, Kim, & Lee, 2015;Miron et al., 2013;Van Steenwinckel et al., 2019;Xu et al., 2017).  Figure S3). GdCl 3 -treated explants demonstrated enhanced myelination by 10 DIV compared to explants exposed to LPS/Hypoxia and vehicle (Figure 4h,i). We confirmed that inhibition of the microglial inflammasome could rescue myelination by application of specific inhibitors of NLRP3 (MCC950) and cleaved caspase-1 (Ac-YVAD) and found that myelination indices were significantly increased at 10 DIV compared to LPS/Hypoxia and vehicletreated explants (Figure 4j,k). These findings indicate that inflammasome activation in microglia causes hypomyelination.
We next sought to determine how microglial inflammasome activation inhibits myelination. We previously identified five proteins which are highly significantly altered in preterm versus term CSF (C5a, IL9, FasL, follistatin, and SPP1) (Boardman et al., 2018), and asked whether these were correlated with levels of IL1β. Whereas in preterm infants, there was poor correlation between IL1β and C5a (r 2 = 0.2863), IL9 (r 2 = 0.04792), FasL (r 2 = 0.01415), and SPP1 (r 2 = 0.4192) ( Figure S4), we found a robust correlation with levels of follistatin (r 2 = 0.7249) ( Figure 5a); there was, however, poor correlation between IL1β and follistatin in term controls (r 2 = 0.2030; Figure 5a). In addition, follistatin protein values were significantly increased in preterm versus term infant CSF (Figure 5b), associating it with increased risk of brain injury. We then asked whether IL1β can induce follistatin expression in microglia. We examined published transcriptomes of microglia from an in vivo model which mimics downstream inflammasome activation by injection of IL1β in mice from postnatal day (P)1 through 5, inducing hypomyelination by P10 ( Figure 5c) (Krishnan et al., 2017). We found that IL1β exposure in vivo increased follistatin (Fst) levels in microglia by P5 and P10 ( Figure 5d). In our explant model, we found increased follistatin protein levels in the conditioned media following treatment with LPS and hypoxia compared to control at 10 DIV (Figure 5e), a time when we observed increased inflammasome activation in microglia. Given that follistatin specifically inhibits activin-A from binding its receptors, and we recently showed that activin-A signaling is required for myelination in development (Dillenburg et al., 2018), we postulated that increased follistatin could impede myelination. Indeed, treating healthy explants with recombinant follistatin from 7 to 10 DIV ( Figure 5f) was sufficient to significantly reduce the myelination index at 10 DIV (Figure 5g,h). Additionally, hypomyelination at 10 DIV following LPS and hypoxia exposure was worsened with follistatin treatment ( Figure 5h). We then asked whether we could alleviate the detrimental effect of follistatin on myelination in injured explants, using two different approaches. First, we blocked follistatin in injured explants by applying a neutralizing antibody during LPS and hypoxia exposure ( Figure 5i). We found that blocking follistatin enhanced myelination compared to LPS and hypoxia-exposed explants treated with isotype IgG control (Figure 5j,k), which reached significance by 21 DIV. Second, we asked whether supplementing injured explants with exogenous activin-A (Figure 5l) could overwhelm the follistatin to allow myelination to take place. We found that activin-A treatment of LPS and hypoxia-exposed explants enhanced myelination index by 21 DIV (Figure 5m,n). These findings reveal an unexpected link between microglial inflammasome activation and activin-A signaling.

| DISCUSSION
By analysis of human infant brain tissue and cerebral spinal fluid combined with the use of a novel explant model of perinatal brain injury, we reveal that developmental hypomyelination is driven by microglial activation of the NLRP3 inflammasome (see Table of Contents Image).
This builds on previous work demonstrating that exogenous application of the inflammasome product IL1β is sufficient to induce hypomyelination in experimental models (Favrais et al., 2011;Krishnan et al., 2017;Mairesse et al., 2019), and that human genetic mutations in NLRP3 causing excess IL1β production are associated with neonatal periventricular white matter lesions (Goldbach-Mansky et al., 2006).
Microglial inflammasome activation in infants may occur due to exposure to two insults within a short time window to provide priming and activation signals. Accordingly, compound insults in infants are associated with severe white matter injury and increased risk of developing cerebral palsy (Barnett et al., 2018;Grether & Nelson, 1997;Hayes et al., 2013;Nelson & Grether, 1998;Wu et al., 2003). Furthermore, clinical contexts often associated with perinatal brain injury-systemic infection, encephalopathy and ischemic stroke-would be predicted to provide signals which induce inflammasome activation, such as pathogen-associated molecular patterns, hypoxia, reactive oxygen and nitrogen species, and calcium fluxes (Hagberg et al., 2015;Yang, Wang, Kouadir, Song, & Shi, 2019). This postulate was affirmed by our demonstration that sequential exposure to the gram-negative E. coli cell wall component LPS and hypoxia was sufficient to induce inflammasome activation in microglia in developing white matter. Additionally, recent work demonstrated that although exposure of developing mouse brain explants to LPS alone primes the inflammasome, it does not lead to inflammasome activation nor mature IL1β production (Hoyle et al., 2020), presumably missing the second stimuli for full inflammasome complex activation.
Consistent with this finding, we observed that a combination of LPS and hypoxia was needed to significantly impact the oligodendrocyte lineage, leading to hypomyelination. This is of translational relevance, as gram-negative bacterial infection contributes to hypomyelination and development of cerebral palsy, and co-existing infection and birth asphyxia significantly increase the risk of perinatal brain injury and cerebral palsy compared to either insult in isolation (Allard et al., 2019;Grether & Nelson, 1997;Hayes et al., 2013;Nelson & Grether, 1998;Wu et al., 2003). Previous experimental work in various models (rodent, sheep, piglet) have shown that LPS sensitizes the brain to subsequent hypoxia to exacerbate developmental brain injury (Bonestroo et al., 2015;Eklind et al., 2001;Kendall et al., 2011;Martinello et al., 2019;Osredkar et al., 2014;Wang et al., 2009). Altogether, this demonstrates that the combination of LPS and hypoxia induces microglial inflammasome activation, which drives white matter pathology similar to that observed in human infants with perinatal brain injury.
We reveal that microglial inflammasome activation induces white matter pathology via regulation of the activin receptor axis. We found a correlation between IL1β and increased levels of the endogenous activin-A inhibitor follistatin in the context of human and mouse developing white matter injury. IL1β is known to modulate follistatin levels and activin receptor signaling in skin and the reproductive system (Arai et al., 2011;Bilezikjian et al., 1998), and here we implicate the crosstalk between these pathways in microglia-driven hypomyelination. We complement our previous work showing that activin receptor signaling is required for myelination in development (Dillenburg et al., 2018), by now demonstrating that increased follistatin levels following perinatal brain injury impair myelination.
Poor myelination was overcome by neutralizing follistatin or supplementation with exogenous activin-A. This leads to the postulate that reinstating activin receptor signaling could represent a promising therapeutic strategy to promote healthy white matter development in injured infants.
Overall, our findings identify a molecular link between dysregulated microglia activation and hypomyelination in perinatal brain injury, and point to novel therapeutic strategies to support white matter health in injured infants centered on inflammasome inhibition and/or reinstatement of activin receptor signaling.